NMDAR inhibition-independent antidepressant actions of ketamine metabolites. - Wikidata - wikimedia - TriplyDB

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

http://www.wikidata.org/entity/Q30370600

about

Ketamine: 50 Years of Modulating the Mind Ketamine's antidepressant action: beyond NMDA receptor inhibition A Clickable Analogue of Ketamine Retains NMDA Receptor Activity, Psychoactivity, and Accumulates in Neurons.A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.Differential Behavioral and Neurobiological Effects of Chronic Corticosterone Treatment in Adolescent and Adult Rats Transient anhedonia phenotype and altered circadian timing of behaviour during night-time dim light exposure in Per3-/- mice, but not wildtype mice.Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state.Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine.S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression.How do antidepressants work? New perspectives for refining future treatment approaches.Experimental medication treatment approaches for depression.Animal models to improve our understanding and treatment of suicidal behavior Decreased Nucleus Accumbens Expression of Psychiatric Disorder Risk Gene Cacna1c Promotes Susceptibility to Social Stress Signaling pathways underlying the antidepressant-like effect of inosine in mice Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain.Investigational drugs in recent clinical trials for treatment-resistant depression.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.The interactive effects of ketamine and magnesium upon depressive-like pathology.Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies.Depression: Ketamine steps out of the darkness Considering Sex as a Biological Variable Will Be Valuable for Neuroscience Research The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models.Ketamine: NMDA Receptors and Beyond.Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model.ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression.Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model.RNA-sequencing profiles hippocampal gene expression in a validated model of cancer-induced depression.Backing into the future: pharmacological approaches to the management of resistant depression Neuropathology of suicide: recent findings and future directions.Ketamine as an adjuvant to opioids for cancer pain.Sex-dependent effects of stress on immobility behavior and VTA dopamine neuron activity: modulation by ketamine.Targeting glutamate signalling in depression: progress and prospects.Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.Kinase-mediated signaling cascades in mood disorders and antidepressant treatment.

P2860

Q28077524-002447EB-B55C-4CD8-AC66-8ED7EFC45FDA Q28278684-37588CEF-BECB-46D8-B333-74F9136EED29 Q28817259-99C4826A-8E6F-410F-AAD0-F47B23B52266 Q30361531-08566211-55D0-42CA-B21D-404ED08C6028 Q30363153-D652BCCB-639C-404C-AFE4-C8DCD65ABCB6 Q30834441-0ABA959F-41BD-4DE0-9E98-FD17F05FD249 Q30848010-871D2F66-D232-4039-9011-9C1B175CFB4A Q30855337-3C9BA37D-D9FE-4686-8DAD-5353F4C6D935 Q33614231-4D03CDAA-CAC7-49AE-9144-FDF734020B39 Q33619029-CAE31D27-E7A1-45E2-BF13-24F3BA7FB2BC Q33635577-6A322A58-C765-404A-925F-29C573B18C69 Q33635653-930B6395-12FA-4992-94D6-9DA39FF4C632 Q33636522-19A25C37-2514-4894-8D46-74FFF53A8A68 Q33689441-32469A19-2562-489C-9F6D-58937520F4BC Q33842686-11C71672-A3D4-4B3C-9466-1A9A828B0EB2 Q33863747-C94536E2-730F-4CCF-A719-014A800BA11D Q34549390-D9779596-371E-436C-BE93-B99AF990687B Q34551188-4FB8F2E5-5754-435F-B09F-CF92CA302091 Q37249086-5CCC588C-4E71-40CC-9A5B-3D8EE212902B Q37279054-57AC9FFB-29CE-4A44-9E1F-3773B9D7F6FE Q37398383-4B1F20C0-4CE6-4332-B4E3-777BE8BD91E9 Q37403546-198080C3-7267-4813-83F0-28C94FF3F618 Q37445074-55221457-1214-4D6A-9C1F-8EB9B6D8AAFA Q37490383-F26157CA-1339-47E0-98FE-3791EF5C2129 Q37490388-49A3B565-3B43-4C69-87B3-7391E0914590 Q37547285-D46C3898-8493-4C7C-A771-152E0C731AF8 Q37583961-5E983E84-F56E-4B58-9724-8AD637CEFFC1 Q37709284-19FE5F38-EBDB-4E5D-8908-8EAE9EF51C96 Q37722650-658214DD-FB04-44A6-8A0D-19224B680BC3 Q37741989-2EFF418D-9125-4FE5-87BE-9DEDF63698C7 Q37745437-4C71EF5F-45AF-4820-9F32-E74777A1867B Q38443525-B92C0248-E9EE-4FED-85DF-2260841CA687 Q38637621-5094E933-6859-4001-AE66-10BC24C87A95 Q38659366-E1128378-BC21-4785-ABEC-55A8C2D83FC9 Q38705422-620EEBCF-4B57-4D41-B0F1-1FBB3F454CFE Q38737919-0F3D9C32-8A31-42A2-9B27-82142700403D Q38743867-DB1F6DE3-68AA-4A9F-9344-D8E9C54E72BC Q38770806-B2D1A5D7-E2DB-486D-88AB-001E775845C9 Q38800909-7EA54A3F-5E67-46D2-A108-8DA2BF08DBAB Q38804430-F98AE80F-63D5-4E74-A700-85AC46EDB529

P2860

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

http://www.wikidata.org/entity/Q30370600

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

@ast

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

@en

type

label

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

@ast

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

@en

prefLabel

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

@ast

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

@en

P1433

Q30370600-D1F942BF-BE7E-4E82-B254-7C963FF1B496

P1476

Q30370600-3AAF5B34-E3CF-4DCA-9B10-8C37D76D0438

P2093

Q30370600-05D0BC7B-AEE8-4E5E-8CBA-DED38C6B3A4D

Q30370600-065C878D-E838-4D7C-878D-471EEB08CF65

Q30370600-0774DD71-AAB9-457C-B710-D21FCACD5F9E

Q30370600-2099C5D0-62C7-484C-A26F-B2CE824F53E4

Q30370600-57825E10-4E39-4EFE-8ADC-1946403928B4

Q30370600-5D190086-1399-4C8D-A6C7-09A7EE9C9A5D

Q30370600-68DC0F1F-2DD5-4FAD-9909-675D087394A5

Q30370600-6EE845B5-53CB-4B43-B472-DA6D00DF07D7

Q30370600-71D543B9-F33D-46DB-BADB-A09005338C40

Q30370600-7DD720D2-526E-4DEE-A1E0-235AD68B3718

P2860

Q30370600-01F09B36-165C-4887-A215-58F5D52F0902

Q30370600-0A0F7E94-0023-45D9-A73F-FCC6150DC183

Q30370600-0A31EF6F-2BA8-4589-8682-932E270E3F6F

Q30370600-161CB810-0025-4EDD-A061-EA67BF6B20BF

Q30370600-16DE993D-FA8B-437D-891E-C3282068AF56

Q30370600-24642DD4-0074-452B-8D6A-57ABFBAC7B03

Q30370600-32256552-1CC1-4D9D-AB29-8CFAFFA377C0

Q30370600-4BE0586C-1DCD-4704-8D34-16782B1B73C4

Q30370600-5555EAAF-E4BE-4C15-9C7F-5D1DAA2EAF5A

Q30370600-561DAC27-EAF5-4D0A-A0BA-9612B52577F6

P2888

Q30370600-FC9B0422-90C0-40B2-9340-EC1820738286

P304

Q30370600-C214EEB6-3083-4B3B-AC7A-9BBBA03E7304

P31

Q30370600-BB7CC056-E576-459F-A4D7-A9DEA6C6D48D

P356

Q30370600-227F6081-6110-4A8E-9C97-41B286AFEDC9

P407

Q30370600-A5C36A79-1790-4E24-A6E4-DC093FFE8B1B

P433

Q30370600-BA34A764-99FB-4C0E-B6DE-6C448322C9C9

P478

Q30370600-8580CAAA-D6FD-4F90-B5AC-63EDE17CE721

P50

Q30370600-927A41E6-40ED-40B6-BB11-F0D6A816CEE4

Q30370600-A4D4BF0E-6DB2-45EB-904C-E620E317F1B4

P577

Q30370600-52FF1A1A-E4BB-41AB-8E5C-74FA387E9237

P6179

Q30370600-5EEFE507-E506-4783-BD29-1806FA7403F3

P698

Q30370600-9F523903-470C-4BAE-B0DD-D9F6C49F2E08

P932

Q30370600-016EECE0-5482-488F-A20A-494A4626F1ED

P356

P1433

P1476

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

@en

P2093

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

Cheryl L Mayo

http://www.w3.org/2001/XMLSchema#string

Craig J Thomas

http://www.w3.org/2001/XMLSchema#string

Edson X Albuquerque

http://www.w3.org/2001/XMLSchema#string

Heather J Pribut

http://www.w3.org/2001/XMLSchema#string

Irving W Wainer

http://www.w3.org/2001/XMLSchema#string

Jonathan Fischell

http://www.w3.org/2001/XMLSchema#string

Katina S S Dossou

http://www.w3.org/2001/XMLSchema#string

Manickavasagom Alkondon

http://www.w3.org/2001/XMLSchema#string

Nagendra S Singh

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Inhibition-based rhythms: experimental and mathematical observations on network dynamics

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.

P2888

P304

481-486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE17998

http://www.w3.org/2001/XMLSchema#string

P407

P433

7604

http://www.w3.org/2001/XMLSchema#string

P478

533

http://www.w3.org/2001/XMLSchema#string

P50

Patrick J Morris

P577

2016-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1000824623

http://www.w3.org/2001/XMLSchema#string

P698

27144355

http://www.w3.org/2001/XMLSchema#string

P932

4922311

http://www.w3.org/2001/XMLSchema#string